# Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

> **NCT01580306** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 32 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** BI 201335
- **DRUG:** BI 201335

## Key facts

- **NCT ID:** NCT01580306
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01580306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01580306, "Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01580306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*